Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Aurinia Pharmaceuticals Inc. (AUPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 4 Bailey Jeffrey Allen (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Granted 17,913 restricted stock units @ $0
Granted 28,959 options to buy @ $9.49, valued at $274.8k
08/21/2023 3 Bailey Jeffrey Allen (Director) has filed a Form 3 on Aurinia Pharmaceuticals Inc.
08/21/2023 4 Smith Karen L. (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Granted 17,913 restricted stock units @ $0
Granted 28,959 options to buy @ $9.49, valued at $274.8k
08/21/2023 3 Smith Karen L. (Director) has filed a Form 3 on Aurinia Pharmaceuticals Inc.
08/21/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia’s Board of Directors August 18, 2023"
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "AURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS"
07/06/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
07/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value In Addition, Board has Accepted Recent Director Resignations and has Initiated a Search for New Directors"
06/01/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
05/26/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/23/2023 4 Balakrishnan Brinda (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Granted 9,310 shares @ $0
Exercised 8,733 restricted stock units @ $0
Granted 15,234 options to buy @ $10.74, valued at $163.6k
05/23/2023 4 Jayne David R.W. (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Granted 9,310 shares @ $0
Sold 8,733 shares @ $11.26, valued at $98.3k
Exercised 8,733 restricted stock units @ $0
Granted 15,234 options to buy @ $10.74, valued at $163.6k
05/23/2023 4 Hagan Joseph P (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Sold 272 shares @ $10.58, valued at $2.9k
Exercised 8,733 restricted stock units @ $0
05/23/2023 4 Billen Daniel (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Granted 9,310 shares @ $0
Sold 4,650 shares @ $11.26, valued at $52.4k
Exercised 8,733 restricted stock units @ $0
Granted 15,234 options to buy @ $10.74, valued at $163.6k
05/23/2023 4 MILNE GEORGE M JR (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Exercised 8,733 restricted stock units @ $0
05/23/2023 4 MacKay-Dunn R. Hector (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Granted 9,310 shares @ $0
Sold 4,818 shares @ $11.26, valued at $54.3k
Exercised 8,733 restricted stock units @ $0
Granted 15,234 options to buy @ $10.74, valued at $163.6k
05/23/2023 4 Leversage Jill (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Granted 9,310 shares @ $0
Sold 4,815 shares @ $11.26, valued at $54.2k
Exercised 8,733 restricted stock units @ $0
Granted 15,234 options to buy @ $10.74, valued at $163.6k
05/11/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
05/10/2023 SC 13D/A ILJIN SNT Co., Ltd. reports a 5% stake in Aurinia Pharmaceuticals Inc.
05/08/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/05/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
05/03/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
05/02/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
04/18/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/05/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial",
"Renal Biopsy Sub-study April 2023"
03/13/2023 8-K Other Events  Interactive Data
03/06/2023 4 MILNE GEORGE M JR (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Bought 20,000 shares @ $8.9142, valued at $178.3k
03/06/2023 4 Donley Matthew Maxwell (EVP, Ops & Strategy) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Granted 271,134 shares @ $0
03/06/2023 4 Miller Joseph M (CFO) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Granted 229,421 shares @ $0
Sold 11,296 shares @ $8.94, valued at $101k
03/06/2023 4 Robertson Stephen P. (EVP, General Counsel) has filed a Form 4 on Aurinia Pharmaceuticals Inc.
Txns: Granted 204,810 shares @ $0
Sold 19,402 shares @ $8.94, valued at $173.5k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy